Anergis Appoints Kim Simonsen as Chief Development Officer − Senior Biotech Executive brings over 25 years of drug development expertise EPALINGES, Switzerland, June 2, 2015 – Anergis, a company developing novel and - Book:Allergies - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-06-02 03:59:18 Immune system Allergen immunotherapy Allergy Allergen Immunotherapy House dust mite Book:Allergies Medicine Immunology Allergology		Anergis Appoints Kim Simonsen as Chief Development Officer − Senior Biotech Executive brings over 25 years of drug development expertise EPALINGES, Switzerland, June 2, 2015 – Anergis, a company developing novel and Add to Reading List Source URL: sunstone.eu Download Document from Source Website File Size: 576,49 KB Share Document on Facebook

	# 3083 AGI-134, a fully synthetic α-Gal-based cancer immunotherapy that shows synergy with anti-PD-1 and favorable pre-clinical pharmacokinetic and toxicity profiles Sascha A. Kristian 1,,#, Stephen M. Shaw 1,, Kim Wi DocID: 1vdls - View Document
	Microsoft Word - ST64 Cancer Immunotherapy v1.0.docx DocID: 1uTyz - View Document
	April 18, 2018 Torii Pharmaceutical Co., Ltd. Price Listing on the NHI Reimbursement List and Launch of “CEDARCURE® Japanese Cedar Pollen Sublingual Tablets”, an Allergen Immunotherapy Tablet for Japanese Cedar Poll DocID: 1uM8x - View Document
	第42回日本免疫学会学術集会クリニカルセミナー 2 Sublingual immunotherapy for Japanese cedar pollinosis DocID: 1untY - View Document
	President of ORPHEUS Robert Adam Harris Professor in Immunotherapy in Neuroinflammation Karolinska Institutet Personal details: DocID: 1u6T9 - View Document